Details of the Drug

General Information of Drug (ID: DMIJ2MZ)

Drug Name
Zifibancimig
Synonyms RG6120
Indication
Disease Entry ICD 11 Status REF
Neovascular age-related macular degeneration 9B78.3Z Phase 1 [1]
Cross-matching ID
TTD ID
D57NHD

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Not Available [2]
Vascular endothelial growth factor (VEGF) TT9HKJA VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Neovascular age-related macular degeneration
ICD Disease Classification 9B78.3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin-2 (ANGPT2) DTT ANGPT2 3.47E-04 -0.31 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04567303) A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Roche